Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Lattanzi

Showing results (11-20 of 48) with videos related to

Pageof 5
Sort By:
Vaccine|March 27, 2012
A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjectsChristoph Hatz, Frank von Sonnenburg, Daniela Casula, et al.
Human Vaccines & Immunotherapeutics|November 27, 2014
A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccinationKeith S Reisinger, Sandra J Holmes, Paola Pedotti, et al.
Human Vaccines & Immunotherapeutics|June 21, 2013
A phase III single arm, multicenter, open-label study to assess the immunogenicity and tolerability of a pentavalent DTwP-HepB-Hib vaccine in indian infantsAdarsh Eregowda, Sanjay Lalwani, Sukanta Chatterjee, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 28, 2010
Clinical efficacy of cell culture–derived and egg‐derived inactivated subunit influenza vaccines in healthy adultsSharon Frey, Timo Vesikari, Agnieszka Szymczakiewicz-Multanowska, et al.
Human Vaccines & Immunotherapeutics|March 16, 2012
Safety assessment and immunogenicity of a cell-culture-derived influenza vaccine in adults and elderly subjects over three successive influenza seasonsAgnieszka Szymczakiewicz-Multanowska, Maria Lattanzi, Allen Izu, et al.
Antimicrobial Agents and Chemotherapy|May 23, 2002
Resistance determinants and clonal diversity in group A streptococci collected during a period of increasing macrolide resistanceStefania Cresti, Maria Lattanzi, Alessandra Zanchi, et al.
Vaccine|October 20, 2009
Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trialWendy Keitel, Nicola Groth, Maria Lattanzi, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|March 10, 2018
Attentional functioning in individuals with 22q11 deletion syndrome: insight from ERPsDaniela Mannarelli, Caterina Pauletti, Tommaso Accinni, et al.
The Journal of Infectious Diseases|August 14, 2009
Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell cultureAgnieszka Szymczakiewicz-Multanowska, Nicola Groth, Roberto Bugarini, et al.
Vaccine|September 10, 2019
MenACWY-CRM conjugate vaccine booster dose given 4-6 years after priming: Results from a phase IIIb, multicenter, open label study in adolescents and adultsMary Tipton, Wendy Daly, Shelly Senders, et al.
Pageof 5

Showing results (11-20 of 48) with videos related to

Sort By:
Pageof 5
Vaccine|March 27, 2012
A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjectsChristoph Hatz, Frank von Sonnenburg, Daniela Casula, et al.
Human Vaccines & Immunotherapeutics|November 27, 2014
A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccinationKeith S Reisinger, Sandra J Holmes, Paola Pedotti, et al.
Human Vaccines & Immunotherapeutics|June 21, 2013
A phase III single arm, multicenter, open-label study to assess the immunogenicity and tolerability of a pentavalent DTwP-HepB-Hib vaccine in indian infantsAdarsh Eregowda, Sanjay Lalwani, Sukanta Chatterjee, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 28, 2010
Clinical efficacy of cell culture–derived and egg‐derived inactivated subunit influenza vaccines in healthy adultsSharon Frey, Timo Vesikari, Agnieszka Szymczakiewicz-Multanowska, et al.
Human Vaccines & Immunotherapeutics|March 16, 2012
Safety assessment and immunogenicity of a cell-culture-derived influenza vaccine in adults and elderly subjects over three successive influenza seasonsAgnieszka Szymczakiewicz-Multanowska, Maria Lattanzi, Allen Izu, et al.
Antimicrobial Agents and Chemotherapy|May 23, 2002
Resistance determinants and clonal diversity in group A streptococci collected during a period of increasing macrolide resistanceStefania Cresti, Maria Lattanzi, Alessandra Zanchi, et al.
Vaccine|October 20, 2009
Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trialWendy Keitel, Nicola Groth, Maria Lattanzi, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|March 10, 2018
Attentional functioning in individuals with 22q11 deletion syndrome: insight from ERPsDaniela Mannarelli, Caterina Pauletti, Tommaso Accinni, et al.
The Journal of Infectious Diseases|August 14, 2009
Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell cultureAgnieszka Szymczakiewicz-Multanowska, Nicola Groth, Roberto Bugarini, et al.
Vaccine|September 10, 2019
MenACWY-CRM conjugate vaccine booster dose given 4-6 years after priming: Results from a phase IIIb, multicenter, open label study in adolescents and adultsMary Tipton, Wendy Daly, Shelly Senders, et al.
Pageof 5